"The group also said the medications would not further delay healing in patients with nonhealing nonvertebral fractures.
Using a structured expert-opinion process, the multidisciplinary panel addressed the use of osteoporosis medicatio"...
MDP-25 Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Marqibo (vinCRIStine sulfate liposome injection) is a vinca alkaloid indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Commonly side effects of Marqibo include:
- low blood pressure
- numbness and tingling or pain in the extremities (peripheral neuropathy)
- low white blood cell count (neutropenia)
- decreased appetite, and
Marqibo is for intravenous use only and is administered at a dose of 2.25 mg/m2 intravenously over 1 hour once every 7 days. Marqibo may interact with antifungal azole drugs, HIV drugs, phenytoin, and St. John's Wort. Tell your doctor all medications you use. Marqibo can cause fetal harm when administered to a pregnant woman. Patients should use effective contraception measures to prevent pregnancy during treatment with Marqibo. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. Patients should not receive Marqibo while pregnant or breastfeeding.
Our Marqibo Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
MDP-25 FDA Prescribing Information: Side Effects
Several cases of allergic dermatological reactions have been reported in association with the use of Technetium Tc 99m Medronate.
Several reactions have also been reported in association with other radiopharmaceuticals of the diphosphonate class, particularly Technetium Tc 99m Medronate. These are usually hypersensitivity reactions characterized by itching, various skin rashes, hypotension, chills, nausea, fever, and vomiting. One death secondary to cardiac arrhythmia following the administration of Technetium Tc 99m Medronate has been reported. In addition, one case of cardiac arrest in a patient also undergoing pulmonary function testing one and one-half hours after the performance of a bone scan using Technetium Tc 99m Medronate has been reported.
Read the entire FDA prescribing information for MDP-25 (Kit for the Preparation of Technetium Tc 99m Medronate Injection)
Additional MDP-25 Information
Report Problems to the Food and Drug Administration
Get tips and advances in treatment.